降压药使用与卵巢癌生存关联研究
该研究基于护士健康研究(NHS)和NHSII队列,评估诊断前(n=950)和诊断后(n=743)使用降压药与侵袭性上皮性卵巢癌生存的关联。调整年龄、BMI、吸烟及肿瘤特征后,诊断前使用钙通道阻滞剂与卵巢癌死亡率升高相关(HR: 1.49; 95% CI: 1.13, 1.96),主要归因于含钙通道阻滞剂的联合治疗(HR: 1.61; 95% CI: 1.15, 2.26)。诊断前使用β受体阻滞剂、噻嗪类利尿剂或ACE抑制剂与卵巢癌死亡率无关;诊断后降压药使用(单独或联合)未见关联,但含ACE抑制剂的联合治疗与较低死亡率相关(HR: 0.53; 95% CI: 0.31, 0.91)。
要点
- 诊断前使用钙通道阻滞剂与卵巢癌死亡率升高相关(HR: 1.49; 95% CI: 1.13, 1.96)。
- 诊断前使用β受体阻滞剂、噻嗪类利尿剂或ACE抑制剂与卵巢癌死亡率无关。
- 诊断后含ACE抑制剂的联合治疗与较低死亡率相关(HR: 0.53; 95% CI: 0.31, 0.91)。
核心结论
- 总体未发现降压药使用与卵巢癌死亡率之间存在明确关系。
- 诊断前使用钙通道阻滞剂与卵巢癌死亡率升高相关,诊断后含ACE抑制剂的联合治疗与较低死亡率相关,需进一步研究。
研究设计与样本
- 前瞻性队列研究,纳入护士健康研究(NHS;1994-2016)和NHSII(2001-2017)中侵袭性上皮性卵巢癌患者。
- 诊断前分析样本n=950,诊断后分析样本n=743,随访至2018年(NHS)和2019年(NHSII)。
- 使用Cox比例风险模型估计降压药使用与卵巢癌死亡的风险比(HR),考虑β受体阻滞剂、钙通道阻滞剂、噻嗪类利尿剂和ACE抑制剂等多类药物。
主要发现
- 调整年龄、BMI、吸烟状态和肿瘤特征后,诊断前使用钙通道阻滞剂 vs 不使用与卵巢癌死亡率升高相关(HR: 1.49; 95% CI: 1.13, 1.96),主要归因于含钙通道阻滞剂的联合治疗(HR: 1.61; 95% CI: 1.15, 2.26)。
- 诊断前使用β受体阻滞剂、噻嗪类利尿剂或ACE抑制剂与卵巢癌死亡率无关。
- 诊断后降压药使用(单独或联合)未见关联,但含ACE抑制剂的联合治疗与较低死亡率相关(HR: 0.53; 95% CI: 0.31, 0.91)。
关键数值与推荐
- 诊断前使用钙通道阻滞剂 vs 不使用:HR: 1.49; 95% CI: 1.13, 1.96。
- 诊断前含钙通道阻滞剂的联合治疗 vs 不使用:HR: 1.61; 95% CI: 1.15, 2.26。
- 诊断后含ACE抑制剂的联合治疗 vs 不使用:HR: 0.53; 95% CI: 0.31, 0.91。
临床怎么用
- 临床医生在为卵巢癌患者开具降压药时,应关注钙通道阻滞剂和ACE抑制剂的潜在生存关联。
- 诊断前使用钙通道阻滞剂的患者可能需要更密切的随访,但需结合个体情况。
- 诊断后含ACE抑制剂的联合治疗可能与较低死亡率相关,但需进一步研究验证。
局限性
- 数据限制无法确定β受体阻滞剂类型是否影响关联。
- 观察到的诊断前钙通道阻滞剂使用和诊断后ACE抑制剂使用关联的原因需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although experimental models suggest that use of beta-blockers, a common antihypertensive agent, may improve survival in ovarian cancer patients, results from clinical studies have been mixed. METHODS: We evaluated the associations of pre-diagnostic (n = 950) and post-diagnostic (n = 743) use of antihypertensive medications with survival among patients with invasive, epithelial ovarian cancer in the Nurses' Health Study (NHS; 1994-2016) and NHSII (2001-2017), with follow-up until 2018 and 2019, respectively. Cox proportional hazards models were used to estimate hazard ratios (HR) for ovarian cancer mortality according to antihypertensive medication use before and after diagnosis, considering multiple drug classes (beta-blockers, calcium-channel blockers, thiazide diuretics, angiotensin-converting enzyme [ACE] inhibitors). RESULTS: After adjusting for age, BMI, smoking status and tumor characteristics, pre-diagnostic use versus non-use of calcium-channel blockers was associated with higher ovarian cancer mortality (HR: 1.49; 95% CI: 1.13, 1.96), which was primarily due to polytherapy involving calcium-channel blockers (HR: 1.61; 95% CI: 1.15, 2.26). Pre-diagnostic use of beta-blockers, thiazide diuretics, or ACE inhibitors was not associated with ovarian cancer mortality. No association was observed for post-diagnostic antihypertensive medication use individually or in combination, except for lower mortality associated with polytherapy involving ACE inhibitors (HR: 0.53; 95% CI: 0.31, 0.91). CONCLUSION: Overall, we did not find clear relationships between antihypertensive medication use and ovarian cancer mortality. However, given the limitation of the data, we cannot determine whether the association may differ by type of beta-blockers. The reasons underlying the observed associations with pre-diagnostic calcium-channel blocker use and post-diagnostic ACE inhibitor use require further investigation.
引用
- Huang T, Townsend MK, Dood RL, et al. Antihypertensive medication use and ovarian cancer survival. Gynecol Oncol. 2021. PMID: 34556331. doi:10.1016/j.ygyno.2021.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。